Long-term persistence of HCV NS5A resistance associated substitutions after treatment with the HCV NS5A inhibitor, ledipasvir, without sofosbuvir | HCV Guidance

HCV Guidance: Recommendations for Testing, Managing, and Treating Hepatitis C

Long-term persistence of HCV NS5A resistance associated substitutions after treatment with the HCV NS5A inhibitor, ledipasvir, without sofosbuvir

Wyles DL, Mangia A, Cheng W, et al. Long-term persistence of HCV NS5A resistance associated substitutions after treatment with the HCV NS5A inhibitor, ledipasvir, without sofosbuvir. Antivir Ther. 2018;23(3):229-238.

Publication Type:

Journal Article

Authors:

Wyles, D.L.; Mangia, A.; Cheng, W; et, al

Source:

Antivir Ther, Volume 23, Issue 3, p.229-238 (2018)

Cited On:

HCV Resistance Primer

Export Citation:

RIS Format

Top